ACAD
32.11
+0.22
+0.69%
AEMD
1.59
-0.09
-5.36%
APRI
1.35
0.00
0.00%
ARNA
21.27
-0.12
-0.56%
ATEC
1.68
-0.01
-0.59%
CNAT
5.06
-0.1
-1.94%
CRXM
0.159
+0.001
+0.72152%
CYTX
0.35
-0.02
-4.40%
DXCM
71.22
-0.4
-0.56%
GNMK
9.99
-0.1
-0.99%
HALO
11.9
-0.15
-1.24%
ILMN
193.92
-0.88
-0.45%
INNV
0.109
+0.008
+7.921%
INO
5.64
0.00
0.00%
ISCO
1.3
-0.05
-3.70%
ISIS
57.56
0.00
0.00%
LGND
127.02
+0.1
+0.08%
LPTN
2.93
-2.93
-100.00%
MBVX
0.511
-0.04
-7.1818%
MEIP
2.77
-0.02
-0.72%
MNOV
4.69
+0.09
+1.96%
MRTX
4.9
+0.05
+1.03%
MSTX
0.13
-0.01
-5.28%
NBIX
54.04
+0.06
+0.11%
NUVA
68
+1.3
+1.95%
ONCS
0.92
-0.06
-5.93%
ONVO
2.14
-0.04
-1.83%
OREX
2.43
0.00
0.00%
OTIC
19.45
+2.25
+13.08%
QDEL
32.93
-0.22
-0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.882
-0.057
-6.0390%
RMD
72.44
-0.83
-1.13%
SCIE
0
+0.00
+50.0000%
SPHS
1.85
+0.02
+1.09%
SRNE
1.65
-0.12
-7.04%
TROV
0.8
-0.05
-5.66%
VICL
2.41
-0.06
-2.43%
VOLC
18
0.00
0.00%
ZGNX
11.45
+0.2
+1.78%
ACAD
32.11
+0.22
+0.69%
AEMD
1.59
-0.09
-5.36%
APRI
1.35
0.00
0.00%
ARNA
21.27
-0.12
-0.56%
ATEC
1.68
-0.01
-0.59%
CNAT
5.06
-0.1
-1.94%
CRXM
0.159
+0.001
+0.72152%
CYTX
0.35
-0.02
-4.40%
DXCM
71.22
-0.4
-0.56%
GNMK
9.99
-0.1
-0.99%
HALO
11.9
-0.15
-1.24%
ILMN
193.92
-0.88
-0.45%
INNV
0.109
+0.008
+7.921%
INO
5.64
0.00
0.00%
ISCO
1.3
-0.05
-3.70%
ISIS
57.56
0.00
0.00%
LGND
127.02
+0.1
+0.08%
LPTN
2.93
-2.93
-100.00%
MBVX
0.511
-0.04
-7.1818%
MEIP
2.77
-0.02
-0.72%
MNOV
4.69
+0.09
+1.96%
MRTX
4.9
+0.05
+1.03%
MSTX
0.13
-0.01
-5.28%
NBIX
54.04
+0.06
+0.11%
NUVA
68
+1.3
+1.95%
ONCS
0.92
-0.06
-5.93%
ONVO
2.14
-0.04
-1.83%
OREX
2.43
0.00
0.00%
OTIC
19.45
+2.25
+13.08%
QDEL
32.93
-0.22
-0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.882
-0.057
-6.0390%
RMD
72.44
-0.83
-1.13%
SCIE
0
+0.00
+50.0000%
SPHS
1.85
+0.02
+1.09%
SRNE
1.65
-0.12
-7.04%
TROV
0.8
-0.05
-5.66%
VICL
2.41
-0.06
-2.43%
VOLC
18
0.00
0.00%
ZGNX
11.45
+0.2
+1.78%
Home » Archive by Category

Syndication

Principal Regulatory Affairs Specialist

July 27, 2017 – 9:30 am

A direct-hire/permanent Principal Regulatory Affairs Specialist job is available in San Diego, CA via Real Staffing. This position is with a leading diagnostic company focused on creating best in class products that provide more timely, precise informatio

Manufacturing Associate, Upstream – Temp-to-Hire – La Jolla Biologics – San Diego, CA

July 27, 2017 – 9:17 am

Flexible shift schedule and overtime may be required. This is a Temporary-to-Hire position scheduled for 40 hours a week….From La Jolla Biologics – Thu, 27 Jul 2017 17:17:00 GMT – View all San Diego, CA jobs

NanoComposix expands its full-service lateral flow assay development services using novel ultra-sensitive nanoparticle reporters, covalent binding chemistry, and quantitative smartphone-based reader technologies to accelerate the development and optimization of lateral flow immunoassays

July 27, 2017 – 7:07 am

SAN DIEGO, July 27, 2017 /PRNewswire/ — nanoComposix, Inc., a global supplier of the widest variety of precisely engineered, highly characterized nanoparticles, has expanded its lateral flow services to provide full-service lateral flow assay development solutions for its medical device customers. NanoComposix’s development team solves sensitivity, sample matrix, and quantification challenges with new ultra-sensitive nanoparticle probes, covalent binding chemistry, and new advances in quantitative smartphone based reader technologies. 

“The fundamental limits of sensitivity in lateral flow diagnostics are dictated by the reporter nanoparticle,” said Dr. Steven Oldenburg, Founder and CEO of nanoComposix.  “With more than a decade of experience building precisely engineered and highly characterized nanomaterials for thousands of customers worldwide, nanoComposix is uniquely positioned to provide the improved particles and chemistry necessary for ultrasensitive, rapid, quantitative, point of care lateral flow diagnostic tests.”

NanoComposix’s proprietary gold nanoshells provide up to a 20-fold increase in sensitivity compared to 40 nm diameter gold nanospheres enabling lateral flow assay tests that were previously not possible.  Unique “bare” gold nanoparticles with a highly displaceable surface optimized for passive adsorption generate stable and reproducible conjugates.  Covalent conjugation chemistry improves conjugate stability in a variety of matrices, provides greater control over per particle antibody loading improving conjugate reproducibility, and, due to higher antibody binding efficiency, can reduce the antibody reagent cost of the assay.  NanoComposix’s full service assay development services leverages the company’s unique expertise to provide rapid development of ISO13485 compliant assays.  Services include feasibility, assay design, antibody pair selection, full strip optimization, prototype cassette design, verification and validation, and transfer to full scale production. For assay quantification, nanoComposix  provides multiple reader options with an emphasis on cell phone-based reader technology. 

About nanoComposix
NanoComposix is a San Diego, California company with the world’s largest variety of metal nanoparticles for biomedical applications in life science, diagnostics, and therapeutics.  GMP and ISO13485 compliant manufacturing methods produce precisely engineered and highly characterized nanoparticles that provide high levels of consistency and performance.  Through the establishment of open and collaborative relationships, we rapidly generate innovative solutions to our clients’ most challenging R&D problems. NanoComposix markets their products directly and through distributors and licensing partners worldwide.

 

View original content:http://www.prnewswire.com/news-releases/nanocomposix-expands-its-full-service-lateral-flow-assay-development-services-using-novel-ultra-sensitive-nanoparticle-reporters-covalent-binding-chemistry-and-quantitative-smartphone-based-reader-technologies-to-accelerate-the–300495375.html

SOURCE nanoComposix

Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails

July 27, 2017 – 4:27 am

Despite all the great progress made harnessing the immune system to fight cancer, there is still much work to be done to maximize its potential. The latest evidence: disappointing results today from…

[[Click headline to continue reading.]]

PetCure Oncology Selects Varian Halcyon Treatment System to Expand Access to Cancer Care for Pets

July 27, 2017 – 4:00 am

PALO ALTO, Calif., July 27, 2017 /PRNewswire/ — According to the National Institutes of Health, an estimated six million dogs and six million cats are diagnosed with cancer each year in the US. Up to now the access to advanced treatments for these treasured family members has been limited. To increase veterinary access to the advanced cancer care already available in human oncology, Varian Medical Systems (NYSE: VAR) and PetCure Oncology today announced a strategic collaboration that will bring an unprecedented level of care to pets suffering from cancer.

The strategic collaboration includes the deployment of Varian’s software suite, including the RapidPlan™ and ARIA® platforms, across PetCure Oncology’s national network of veterinary cancer care centers. In addition, PetCure Oncology will acquire six Varian Halcyon treatment systems for use in select sites across the US, providing access to the latest in radiation therapy technology to pets.

PetCure plans to leverage the many features of Halcyon, including its reduced facilities requirements and ease-of-use, to expand the availability of high quality cancer care for animals.  PetCure is scheduled to install the first system in late-August 2017.

“PetCure understands the impact a pet’s cancer diagnosis has on a family,” said Scott Milligan, CEO of PetCure Oncology. “We are committed to delivering them the highest level of cancer care and support. This strategic partnership with Varian ensures that our network of veterinary radiation oncologists has direct access to the best available clinical resources.”

“We are excited about this opportunity with PetCure and its ability to deliver high quality treatments to many more pets,” said Chris Toth, president of Global Commercial and Field Operations at Varian. “The use of RapidPlan to leverage the knowledge of previous treatments across PetCure’s network and project it to future cases is a game changer in veterinary radiation therapy.”

For more information on Halcyon, visit www.varian.com/halcyon.

About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world’s leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

About PetCure Oncology

PetCure Oncology specializes in radiation oncology for pets, partnering with leading specialty animal hospitals around the country to collaboratively offer comprehensive cancer care. Two new sites are scheduled to open this summer in San Jose and Jacksonville, joining established centers in Pittsburgh (PA), Phoenix (AZ), Clifton (NJ), Milwaukee (WI) and Cincinnati (OH) in providing human-caliber cancer care to pets. To learn more about PetCure Oncology, visit PetCureOncology.com.

Press Contacts

Mark Plungy
Varian Medical Systems
+1 (650) 424-5630
mark.plungy@varian.com

Neil Madle
Varian Medical Systems
+44 7786 526068
neil.madle@varian.com

Jack Moore
PetCure Oncology
+1 (847) 420-5594
jmoore@petcureoncology.com

 

View original content:http://www.prnewswire.com/news-releases/petcure-oncology-selects-varian-halcyon-treatment-system-to-expand-access-to-cancer-care-for-pets-300494992.html

SOURCE Varian Medical Systems

Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia

July 27, 2017 – 4:00 am

PCM-075, in combination with decitabine, in patients with Acute Myeloid Leukemia (AML) for exploration of the safety, tolerability, dose and scheduling, and antitumor activity

SAN DIEGO, July 27, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for PCM-075, a Polo-like Kinase 1 (PLK1) inhibitor, and has provided authorization to proceed with the treatment of patients with AML. Trovagene submitted its IND for a Phase 1b/2 clinical trial of PCM-075 in patients with AML to the FDA on June 27, 2017.

The Phase 1b/2 clinical trial will be led by Hematologist Jorge Eduardo Cortes, M.D., Deputy Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

“The FDA’s timely acceptance of our IND application and Phase 1b/2 protocol is an important milestone for Trovagene,” said Bill Welch, Chief Executive Officer of Trovagene. “We have already received positive indications of interest from numerous key investigators and clinical institutions as we make preparations to initiate our trial in the U.S.  Also, we are fortunate to have Dr. Cortes as the Principal Investigator on our trial given his vast experience in leukemia and his prior work with PLK1 inhibitors.”

Clinical Study Details

The Phase 1b/2 is an open-label trial to evaluate the safety and anti-leukemic activity of PCM-075 in combination with decitabine in subjects with AML. The Phase 1b subjects will have relapsed, or have resistant disease to three or fewer prior therapeutic regimens. The Phase 2 subjects will have received no more than one prior regimen for the treatment of their AML, have either relapsed or refractory disease, and are judged not to be candidates for re-induction therapy. Newly diagnosed subjects will be included if they have not received prior therapy for their disease, and are ineligible for, or have refused, standard intensive induction therapy.

The Phase 1b is a dose escalation trial of PCM-075 in combination with decitabine to evaluate drug safety, tolerability, dose and scheduling, and determine a recommended clinical treatment dose for the Phase 2 continuation trial. The initial Phase 1b dose level of 12 mg/m2/day will be increased by 50% increments to reach the maximum clinical dose for AML patients. Pharmacokinetics of PCM-075 and correlative biomarker activity will be assessed prior to the initiation of Phase 2.

The Phase 2 continuation trial is open-label with administration of the recommended PCM-075 clinical dose in combination with decitabine. Doses of PCM-075 will be administered orally each day for five consecutive days in a 28-day cycle in both Phase 1b and Phase 2. Trovagene expects approximately 60 patients to be dosed with PCM-075 and evaluated in the Phase 1b/2 trial.  PCM-075 will be supplied as hard gelatin capsules and will be manufactured by NerPharMa, a pharmaceutical manufacturing company and a subsidiary of Nerviano Medical Sciences.

About Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematologic malignancy in which myeloid lineage cells of the bone marrow cease to differentiate appropriately, resulting in a marked increase in the number of circulating immature blast cells. As a consequence, the counts of mature red blood cells, platelets, and normal white blood cells decline, causing fatigue, shortness of breath, bleeding, and increased susceptibility to infection. The Surveillance, Epidemiology and End Results (SEER) program estimates the annual incidence rate of AML in the United States (US) to be approximately 21,000 cases in 2017. Rates of new AML cases have been rising an average of 3.1% each year over the last 10 years. The median age of AML diagnosis is 68 years of age, and approximately 45% of new diagnoses are among patients age 70 years or older.

About PCM-075

PCM-075 is a highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in several different hematologic malignancies, as well as solid tumors such as breast, prostate, ovarian, lung, gastric and colon cancers. PCM-075 is orally bioavailable and has been explored in an initial Phase 1, open-label, dose-escalation safety study in patients with advanced metastatic solid tumor cancers. Trovagene plans to initiate clinical trials of PCM-075 in AML, since it has significant advantages over prior PLK1 inhibitors evaluated in this indication, including a higher selectivity, greater potency, oral bioavailability and shorter half-life.

About Trovagene, Inc.

Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  For more information, please visit https://www.trovagene.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Trovagene’s expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.  There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful, or that Trovagene’s strategy to design its liquid biopsy tests to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes.  Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2016, and other periodic reports filed with the Securities and Exchange Commission.  While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties.  Unlisted factors may present significant additional obstacles to the realization of forward-looking statements.  Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Trovagene Contact:
Vicki Kelemen
VP, Corporate Communications
858-952-7652
vkelemen@trovagene.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/trovagene-announces-fda-approval-of-ind-for-phase-1b2-trial-of-pcm-075-in-patients-with-acute-myeloid-leukemia-300495015.html

SOURCE Trovagene, Inc.

Customer Solutions Development Engineer / Scientist 2 – Illumina – San Diego, CA

July 26, 2017 – 10:43 pm

Responsible for advocating for customer and support needs, driving strategic support planning activities and managing execution of support deliverables….From Illumina – Thu, 27 Jul 2017 06:43:54 GMT – View all San Diego, CA jobs

Validation Engineer 2 – Illumina – San Diego, CA

July 26, 2017 – 10:43 pm

Provide day-to-day support to development, engineering and manufacturing for design control planning and design transfer activities….From Illumina – Thu, 27 Jul 2017 06:43:46 GMT – View all San Diego, CA jobs

Commissioning Technician 3 – EMD – Carlsbad, CA

July 26, 2017 – 10:13 pm

3 to 5 years of experience in Pharmaceutical/ Biotech in an Engineering, Commissioning, Validation or QA role….From EMD – Thu, 27 Jul 2017 06:13:25 GMT – View all Carlsbad, CA jobs

Chemical Compound Coordinator – VWR – San Diego, CA

July 26, 2017 – 8:38 pm

With sales in excess of $4.3 billion in 2015, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and…From VWR – Thu, 27 Jul 2017 04:38:22 GMT – View all San Diego, CA jobs